Issue 4/2006
Content (13 Articles)
The Wnt-dependent signaling pathways as target in oncology drug discovery
Nico Janssens, Michel Janicot, Tim Perera
Population pharmacokinetics and bioavailability of motexafin gadolinium (Xcytrin®) in CD1 mice following intravenous and intraperitoneal injection
Boswell GW, DR Miles, PA Thiemann, M Mesfin
Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients
Jing Li, Julie Brahmer, Wells Messersmith, Manuel Hidalgo, Sharyn D. Baker
A phase I Study with oral SU5416 in patients with advanced solid tumors: A drug inducing its clearance
Marc Salzberg, Miklos Pless, Christoph Rochlitz, Klara Ambrus, Paul Scigalla, Richard Herrmann
A phase I study of flavopiridol and docetaxel
Basil F. El-Rayes, Shirish Gadgeel, Ralph Parchment, Patricia Lorusso, Philip A. Philip
A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors
Werner Hilgers, Sandrine Faivre, Stéphanie Chieze, Jérôme Alexandre, François Lokiec, François Goldwasser, Eric Raymond, Carmen Kahatt, Abdelkrim Taamma, Garry Weems, John R. MacDonald, Jean-Louis Misset, Esteban Cvitkovic
Phase I trial of thalidomide and Interleukin-2 in patients with metastatic renal cell carcinoma
Thomas Olencki, Sareena Malhi, Tarek Mekhail, Robert Dreicer, Paul Elson, Laura Wood, Ronald M. Bukowski
A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors
Thierry Delaunoit, Patrick A. Burch, Joel M. Reid, John K. Camoriano, Tomowo Kobayash, Theodore A. Braich, Judith S. Kaur, Joseph Rubin, Charles Erlichman
Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: A Southwest Oncology Group study
Robert P. Whitehead, Sheryl McCoy, John S. Macdonald, Saul E. Rivkin, Marcus A. Neubauer, Shaker R. Dakhil, Heinz-Josef Lenz, Michael S. Tanaka, James L. Abbruzzese
A phase II study of chloroquinoxaline sulfonamide (CQS) in patients with metastatic colorectal carcinoma (MCRC)
Tanios S. Bekaii-Saab, Amir Mortazavi, Lee G. Hicks, Mark Zalupski, Robert J. Pelley, Kenneth K. Chan, Eric H. Kraut
SarCNU in recurrent or metastatic colorectal cancer: A phase II study of the National Cancer Institute of Canada Clinical Trials Group
R. P. Wong, T. Baetz, M. J. Krahn, J. Biagi, N. Wainman, E. Eisenhauer
A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma
Jaffer A. Ajani, Yixing Jiang, Josephine Faust, Baochong B. Chang, Linus Ho, James C. Yao, Steven Rousey, Shaker Dakhil, Richard C. Cherny, Catherine Craig, Archie Bleyer
Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapy
Hitendra Patel, Ronald Stoller, Miklos Auber, Douglas Potter, Chao Cai, William Zamboni, Gauri Kiefer, Khalid Matin, Amy Schmotzer, Ramesh K. Ramanathan